We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-6.51%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$202M
AUM Growth
-$68.1M
(-25%)
Cap. Flow
+$37.7M
Cap. Flow
% of AUM
18.62%
Top 10 Holdings %
Top 10 Hldgs %
75.02%
Holding
62
New
16
Increased
10
Reduced
11
Closed
18
Avg Time Held Equity + Options
3.5
quarters
Top 10 Avg Time Held Equity + Options
2.2
quarters
Top 20 Avg Time Held Equity + Options
1.6
quarters
Avg Time Held Equity only
3.5
quarters
Top 10 Avg Time Held Equity only
2.7
quarters
Top 20 Avg Time Held Equity only
1.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$30.7M |
| 2 |
GE HealthCare
GEHC
|
+$14.1M |
| 3 |
Cigna
CI
|
+$10.1M |
| 4 |
ADC Therapeutics
ADCT
|
+$7.97M |
| 5 |
Bicycle Therapeutics
BCYC
|
+$7.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
|
+$23.4M |
| 2 |
STAAR Surgical
STAA
|
+$7.63M |
| 3 |
Icon
ICLR
|
+$6.6M |
| 4 |
HSKA
Heska Corp
HSKA
|
+$5.61M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$4.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.68% |
| 2 | Miscellaneous | 1.32% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Centene
CNC
$34.1B
| $27.4M | 13.53% |
+432,834
| New | +$30.7M |
2023 Q1
0 quarters
|
|
|
2
Cigna
CI
$76.1B
| $22.3M | 11.01% |
87,175
+34,564
| +66% | +$10.1M |
2020 Q3
10 quarters
|
|
|
3
Bicycle Therapeutics
BCYC
$248M
| $20.6M | 10.17% |
967,347
+283,922
| +42% | +$7.12M |
2021 Q4
5 quarters
|
|
4
Cencora
COR
$63.7B
| $20.5M | 10.14% |
128,164
+43,765
| +52% | +$6.94M |
2021 Q4
5 quarters
|
|
5
United Therapeutics
UTHR
$23.1B
| $16.8M | 8.3% |
75,003
+20,044
| +36% | +$4.94M |
2018 Q4
17 quarters
|
|
|
6
GE HealthCare
GEHC
$30.9B
| $16.2M | 7.98% |
+196,887
| New | +$14.1M |
2023 Q1
0 quarters
|
|
7
Organon & Co
OGN
$3.62B
| $11.1M | 5.48% |
471,553
-116,283
| -20% | -$3.12M |
2022 Q2
3 quarters
|
|
8
Medtronic
MDT
$119B
| $6.77M | 3.35% |
84,012
-43,988
| -34% | -$3.59M |
2022 Q4
1 quarter
|
|
9
Avantor
AVTR
$10.7B
| $5.99M | 2.96% |
283,136
+33,136
| +13% | +$755K |
2022 Q4
1 quarter
|
|
|
10
ADC Therapeutics
ADCT
$192M
| $4.21M | 2.08% |
+2,160,632
| New | +$7.97M |
2023 Q1
0 quarters
|
|
11
Viking Therapeutics
VKTX
$3.29B
| $4.16M | 2.06% |
+250,000
| New | +$2.58M |
2023 Q1
0 quarters
|
|
12
DELISTED
Axonics, Inc. Common Stock
AXNX
| $3.87M | 1.91% |
+70,841
| New | +$4.14M |
2023 Q1
0 quarters
|
|
13
Globus Medical
GMED
$10.2B
| $3.82M | 1.89% |
+67,500
| New | +$4.33M |
2023 Q1
0 quarters
|
|
14
Relay Therapeutics
RLAY
$3.74B
| $3.79M | 1.87% |
+230,013
| New | +$4.12M |
2023 Q1
0 quarters
|
|
15
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $3.35M | 1.66% |
272,843
+22,843
| +9% | +$268K |
2022 Q4
1 quarter
|
|
16
Revolution Medicines
RVMD
$41.9B
| $2.73M | 1.35% |
+125,957
| New | +$3.1M |
2023 Q1
0 quarters
|
|
|
EUCRU
17
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $2.58M | 1.27% |
248,674
| – | – |
2020 Q4
9 quarters
|
|
18
DELISTED
Repare Therapeutics
RPTX
| $2.25M | 1.11% |
+228,538
| New | +$2.62M |
2023 Q1
0 quarters
|
|
|
CTIC
19
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $2.21M | 1.09% |
526,239
+196,239
| +59% | +$1.02M |
2022 Q4
1 quarter
|
|
20
Savara
SVRA
$968M
| $1.85M | 0.91% |
948,457
+82,009
| +9% | +$185K |
2021 Q4
5 quarters
|
|
21
Pharvaris
PHVS
$2.1B
| $1.84M | 0.91% |
228,385
-56,615
| -20% | -$498K |
2022 Q4
1 quarter
|
|
|
HSKA
22
DELISTED
Heska Corp
HSKA
| $1.7M | 0.84% |
17,450
-66,859
| -79% | -$5.61M |
2022 Q4
1 quarter
|
|
23
DELISTED
Elevation Oncology
ELEV
| $1.67M | 0.82% |
876,611
+516,880
| +144% | +$667K |
2021 Q4
5 quarters
|
|
24
Inogen
INGN
$164M
| $1.52M | 0.75% |
121,535
-165,157
| -58% | -$3.16M |
2021 Q4
5 quarters
|
|
25
Nyxoah
NYXH
$127M
| $1.41M | 0.7% |
188,875
+172,765
| +1,072% | +$969K |
2021 Q3
6 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Sio Capital Management held 62 positions worth $202M, down 25% from $270M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Sio Capital Management deployed $37.7M of net new capital in Q1 2023, opening 16 new positions and adding to 10 existing holdings. Its largest new stake was Centene: 432,834 shares worth $27.4M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 60% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Heska Corp, an estimated $5.61M trimmed.
- Sio Capital Management's largest Q1 2023 buy was Centene: 432,834 shares worth $27.4M.
- Sio Capital Management added most to Cigna in Q1 2023, an estimated $10.1M increase.
- Sio Capital Management's biggest Q1 2023 reduction was Heska Corp, cutting an estimated $5.61M.
- Sio Capital Management fully exited Medicus Sciences Acquisition Corp. Class A Ordinary Share in Q1 2023, selling an estimated $23.4M.
- Sio Capital Management's ten largest holdings make up 75% of its $202M portfolio in Q1 2023.
- Sio Capital Management opened 16 new positions and closed 18 in Q1 2023.
- Sio Capital Management's portfolio value fell 25% quarter-over-quarter to $202M.
Based on Sio Capital Management's 13F filing for Q1 2023, filed 12 May 2023.